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Protein O-fucosyltransferase2 (Pofut2)a b s t r a c t
The matricellular protein CCN1, also known as Cyr61, is a secreted ligand and has numerous func-
tions. Human CCN1 contains one predicted O-fucosylation site in the thrombospondin type-1 repeat
(TSR1) domain at Thr242. In this report, we demonstrated that CCN1 is O-fucosylated at Thr242 using
mass spectrometry. Deficiency of O-fucosylation resulted in the decrement of the cell surface local-
ization and the secretion of CCN1. Furthermore, knockdown of protein O-fucosyltransferase 2,
which modifies a specific Ser/Thr residue in the TSR1 domain, decreased secreted levels of CCN1.
These results demonstrated that O-fucosylation of CCN1 at Thr242 regulates its secretion.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Matricellular protein CCN1, also known as Cyr61, is a member
of the growth factor-inducible immediate-early genes and belongs
to CCN family proteins, which are the secreted cysteine-rich pro-
teins [1–4]. Human CCN family contains six members, CCN1–6
[4,5]. All CCN family proteins have an N-terminal signal peptide,
followed by four functional domains—insulin-like growth factor-
binding protein (IGFBP) N-terminal domain, von Willebrand factor
type C repeat (vWC), thrombospondin type-1 repeat (TSR1), and
cysteine knot motif (CT) in order—except CCN5, which lacks CT
[5–7]. Since CCN proteins are bisected by a central hinge region
with each half of the molecule binding different receptors, CCN
family proteins are involved in numerous biological processes
[4,6,8]. CCN1, a member of CCN family proteins, interacts with
various receptors, such as heparan sulfate proteoglycans (HSPGs)and some types of integrins [9–11]. Thus, it has diverse functions,
such as cell proliferation, adhesion, migration, differentiation,
apoptosis, angiogenesis, and tumorigenesis [4,12–14]. While
CCN1 plays crucial roles for cell proliferation, embryogenesis,
inflammation, and tissue repair in many adult tissues, aberrant
expression of CCN1 induces tumorigenesis and tumor progression,
especially in breast, gastric, and pancreatic cancers [15–20]. From
these studies, CCN1 may hold promise in the development of
diagnostic markers or therapeutics [4].
O-fucosylation is one of the post-translational modifications in
which an O-linked fucose is attached to the hydroxyl group of a
certain Ser/Thr residue [21,22]. It has been reported that two inde-
pendent O-fucosylation pathways, epidermal growth factor (EGF)-
like repeat and TSR1, are O-fucosylated by endoplasmic reticulum
(ER)-localized soluble enzymes, the protein O-fucosyltransferase1
(Pofut1) and Pofut2, respectively [23–26]. Pofut1 modifies a
specific Ser/Thr residue in the consensus sequence C-X4–5-(S/T)-C
of EGF-like repeats [22], and further modifications can be extended
by the sequential enzymatic activity of Fringe, b1,4-galactosyltrans
ferase 1, and a2,3/a2,6-sialyltransferase, resulting in NeuAc-a2,3/
a2,6-Gal-b1,4-GlcNAc-b1,3-Fuc tetrasaccharide [27,28]. O-fuco-
sylation of EGF-like repeats by Pofut1 has been well studied, and
this modification plays a crucial role in Notch signaling [29,30].
Knockout of the Pofut1 gene in mice causes embryonic death at
E9.5 due to severe Notch signaling defects [30], which is consistent
with the function of O-fucosylation of EGF-like repeats by Pofut1 in
the cell. In contrast, the role of Pofut2-mediated O-fucosylation of
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to a specific Ser/Thr residue in the consensus sequence
C-X2-3-(S/T)-C-X2-G of TSR1 [22,31], and it can be further
modified by glucose-b1,3-glucosyltransferase, resulting in
Glc-b1,3-Fuc disaccharide [32,33]. It was reported that
O-fucosylation is required for secretion in some proteins [34,35].
Knockout of the Pofut2 gene in mice results in embryonic lethality
at E10.5 due to gastrulation defects [36]; however, why knockout
of Pofut2 triggers gastrulation defects remains unclear [22]. To
solve this question and extend knowledge about Pofut2-mediated
O-fucosylation, identification of O-fucosylated proteins by Pofut2 is
required.
Human CCN1 has one predicted O-fucosylation site (Thr242)
within TSR1; however, it has not been reported whether CCN1 is
O-fucosylated or not. In this report, we demonstrated the first
evidence that CCN1 is O-fucosylated at Thr242, and O-fucosylation
of CCN1 regulates its secretion. Since secretion is an initial step
for CCN1 to function as a ligand and is required for its biological
functions, the regulation of CCN1 secretion by O-fucosylation is a
significant finding and may be a new target for cancer therapy.
2. Materials and methods
2.1. Cell culture
A human fibrosarcoma HT1080 cell line was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% (v/v) fetal bovine serum, 100 units/mL penicillin G, 100 mg/L
kanamycin, 600 mg/L L-glutamine, and 2.25 g/L NaHCO3 at 37 C
in a humidified incubator with 5% CO2.
2.2. Construction of CCN1 expression plasmid and site-directed
mutagenesis
The human CCN1 cDNA was amplified from an MDA-MB-231
human breast cancer cell cDNA library and subcloned into the
pCI-neo vector (Promega). To introduce the C-terminal myc-his6
tag, we performed PCR with primers that have myc and his6
codons. The sequences of the tags were as follows: myc; GAA
CAAAAACTCATCTCAGAAGAGGATCTG, and his6; CATCATCACCAT-
CACCAT. We substituted certain Thr residues in CCN1 with Ala
residues by PCR site-directed mutagenesis using overlap extension
technique. The sequences of primers used for the mutagenesis
were as follows: T242A, 50-GTCCCAGTGCTCAAAGGCCTGTG
GAACTGGTATC-30 (forward) and 50-GATACCAGTTCCACAGGCCTTT
GAGCACTGGGAC-30 (reverse).
2.3. Establishment of CCN1-overexpressing cell lines
The permanent cell lines expressing wild-type or mutant CCN1-
myc-his6 were established by transfecting the vectors into HT1080
cells, followed by 400 lg/mL G418 (Roche Applied Sciences)
selection [37–39]. The clone cells that expressed high levels of
myc-his6-tagged wild-type CCN1 and CCN1 (T242A mutant) were
designated HT1080-CCN1-MH and HT1080-CCN1/T242A-MH cells,
respectively. The cells transfected with pCI-neo were designated
HT1080-neo.
2.4. Western blot
To perform western blot, we used a slightly modified version of
a previously described method [40,41]. Cells were cultured and
lysed in a lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, 1% (w/v) sodiumdeoxycholate, and 1 mM phenylmethylsulfonyl fluoride) at 4 C
with sonication. The lysates were centrifuged at 20000g for
10 min, and the amount of protein in each lysate was measured
by staining with Coomassie Brilliant Blue (CBB) G-250 (Bio-Rad
Laboratories). A loading buffer (350 mM Tris–HCl, pH 6.8, 30%
(w/v) glycerol, 0.012% (w/v) bromophenol blue, 6% (w/v) SDS,
and 30% (v/v) 2-mercaptoethanol) was added to each lysate, which
was subsequently boiled for 3 min and electrophoresed on
SDS–polyacrylamide gels. Proteins were transferred to PVDF
membranes and immunoblotted with anti-c-myc antibody, which
was deposited to the DSHB by Bishop, J. Michael (DSHB Hybridoma
Product 9E10). Detection was performed with enhanced chemilu-
minescence reagent (Immobilon Western Chemiluminescent HRP
substrates, Millipore Corporation) by an ImageQuant LAS4000mini
(GE Healthcare).
2.5. Detection of secreted CCN1
Cells were washed with phosphate-buffered saline (PBS) twice
and were cultured in serum-free DMEM for 24 h with or without
50 lg/mL heparin (Sigma). The conditioned medium (CM) was
collected, and the cell lysate was prepared as described above.
Loading buffer was added to both conditioned medium and cell
lysate, which was boiled for 3 min. Subsequently, the proteins
were separated on SDS–PAGE and analyzed by immunoblot with
anti-c-myc antibody.
2.6. Purification of recombinant wild-type CCN1 from cell culture
medium for MALDI-TOF MS analysis
Cells were washed with PBS twice and were cultured in serum-
free DMEM for 24 h with 1% (v/v) heparin sepharose 6 fast flow (GE
Healthcare). After 24 h, heparin sepharose beads were collected,
washed with PBS twice, and eluted with buffer A (900 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 20 mM imida-
zole). The Ni–NTA agarose was added, and the mixture was incu-
bated for 2 h at 4 C and eluted with 500 mM imidazole. The
obtained samples were electrophoresed on an SDS–polyacrylamide
gel. The protein bands were visualized by CBB R-250.
2.7. MALDI-TOF MS analysis
Purified recombinant CCN1 was subjected to SDS–polyacry-
lamide gel electrophoresis. After CBB staining, the bands were
excised and treated with 0.05 lg of sequencing-grade TPCK-
trypsin (Worthington Biochemical) at 37 C for 12 h in 0.1 M
Tris–HCl, pH 8.0, followed by reduced propionamidation. The
digests were desalted using Zip TipC18l (Millipore Corporation)
and applied to MALDI-TOF MS on an ultrafleXtreme TOF/TOF MS
mass spectrometer (Bruker Daltonics) in reflector mode using a-
cyano-4-hydroxycinnamic acid as a matrix. The selected peaks
were analyzed by MS/MS in LIFT mode.
2.8. Semi-quantitative RT-PCR
To perform semi-quantitative RT-PCR, we used a slightly mod-
ified version of previously described methods [37,41]. Total RNAs
were extracted from cultured cells by using Trizol reagent (Invitro-
gen) according to the manufacturer’s method, and solutions con-
taining 2 lg of total RNAs were taken for the reverse-
transcription reaction that was performed with the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Reverse-transcribed cDNA was used for PCR amplification with
Quick Taq HS DyeMix (Toyobo). The sequences of the primers used
Y. Niwa et al. / FEBS Letters 589 (2015) 3287–3293 3289for semi-quantitative RT-PCR, the numbers of cycles, and the
annealing temperatures were as follows: CCN1-MH, 50-ATGAGCT
CCCGCATCGCCAGGGCGCTCGCCTTAG-30 (forward) and 50-GTGATG
GTGATGATGCAGATCCTCTTCTGAGATGAG-30 (reverse), 25 cycles,
63 C; Pofut2, 50-ATGGCGACACTCAGCTTCGTCTTCCTGCTGCTG-30
(forward) and 50-TCAGTAGGTGATCTTCCAGTGGGTGGGTTGCTC-30
(reverse), 31 cycles, 63 C; b-actin, 50-CTTCTACAATGAGCTGCGTG-
30 (forward) and 50-TCATGAGGTAGTCAGTCAGG-30 (reverse), 20
cycles, and 58 C. PCR products were electrophoresed on agarose
gels, stained with ethidium bromide, and visualized with an LED
illuminator (Bio Craft).
2.9. Immunofluorescence
HT1080-neo, HT1080-CCN1-MH, and HT1080-CCN1/T242A-MH
cells were grown on coverslips with or without 50 lg/mL heparin.
After 24 h, the cells were washed with PBS and fixed with 4%
paraformaldehyde for 10 min. After blocking with 3% bovine serum
albumin, the cells were incubated with mouse monoclonal
anti-c-myc antibody for 1 h. Alexa Fluor488-conjugated
anti-mouse IgG (Molecular Probes) was used as a secondary
antibody. After being washed two additional times, the cells were
incubated with 2 lg/mL Hoechst 33258 (Polysciences, Inc.) for
10 min to stain the nuclei. The cells were washed with PBS andA
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2.10. Knockdown of Pofut2
Cells were transfected with 20 nM of each siRNA using Lipofec-
tamine RNAiMAX (Invitrogen). The efficiencies of the siRNAs
against the expression of each target gene were monitored by
semi-quantitative RT-PCR. The sequences of the siRNAs were as
follows: siPofut2#1, GUACUACAGAGGAUGGUUUdTdT; siPofut2#2,
CGUCAGAAAGGAAUAUGAAdTdT. siCtrl (4611G) was purchased
from Life Technologies.
3. Results
3.1. O-fucosylation of CCN1 at Thr242
The amino acid sequence of the human CCN1 protein has one
predicted O-fucosylation site at the Thr242 residue in the TSR1
(Fig. 1A and B). Since the O-fucosylation consensus sequence medi-
ated by Pofut2 (C-X2–3-(S/T)-C-X2-G) is conserved in all human
CCN1–6 in the TSR1 (Fig. 1B), O-fucosylation of CCN family proteins
was predicted to have important roles in their functions. To
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Fig. 2. Determination of O-fucosylation site within CCN1. (A) Purification of recombinant human CCN1 protein from the CM of HT1080-CCN1-MH cells. Cells were cultured
with heparin sepharose beads for 24 h, and the beads were collected. The proteins bound to heparin were washed and eluted, and CCN1-MH was purified with
Ni–NTA agarose. Samples were electrophoresed on an SDS–polyacrylamide gel and visualized with CBB. (B and C) Determination of O-fucosylation site within CCN1. Purified
CCN1 was digested with trypsin, and the resulting peptides were analyzed by MALDI-TOF MS (B). The observed masses (m/z 2706.4 and 2868.5) corresponded well to the
expected masses of the trypsin-digested peptide 229CIVQTTSWSQCSKTCGTGISTR250, which contains a putative O-fucosylation site (Thr242), modified by dHex and dHex-Hex
(B). The peptides modified by dHex (upper) and dHex-Hex (lower) were analyzed by MALDI-TOF MS/MS (C). Observed peaks of these fragments are the indicated y-ions.
Putative O-fucosylation site (Thr242) is indicated in red characters. Propionamide cysteine is indicated in blue characters.
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Fig. 3. O-fucosylation of CCN1 regulates its secretion. (A and B) Establishment of an O-fucosylation-defective mutant CCN1-overexpressing HT1080 cell line, HT1080-CCN1/
T242A-MH cell. HT1080-neo (neo), HT1080-CCN1-MH (wt), and HT1080-CCN1/T242A-MH (T242A) cells were lysed, and aliquots of the cell lysates were electrophoresed and
immunoblotted with anti-c-myc antibody. The membrane after immunoblotting was visualized with CBB (A). Total RNAs were isolated from each cell line, and semi-
quantitative RT-PCR was performed (B). Equal amounts of exogenous CCN1 in the stable cell lines were confirmed. (C) Effect of O-fucosylation on cellular membrane
localization of CCN1. Each cell was cultured with or without 50 lg/mL soluble heparin. After 24 h, unpermeabilized cells were fixed and stained with Hoechst 33258 (blue)
and anti-c-myc antibody (green). The samples were observed by fluorescence microscopy. Bar, 10 lm. (D) Effect of O-fucosylation on CCN1 secretion. Each cell was cultured
with 50 lg/mL soluble heparin. After 24 h, each cell lysate and CM were collected, and the samples were electrophoresed and immunoblotted with anti-c-myc antibody. The
membrane after immunoblotting was visualized with CBB. Non-O-fucosylated CCN1 substantially inhibited the secretion.
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(Fig. 1C). Although CCN1 has an N-terminal signal peptide and is
likely to be secreted into conditioned medium (CM), we could
not detect secreted CCN1 in CM (Fig. 1D). CCN1 is reported to bind
to cell surface HSPGs with high affinity [11]; so, we treated cells
with soluble heparin in order to detach CCN1 from HSPGs. As a
result, secreted CCN1 was detected in concert with heparin treat-
ment (Fig. 1D).
To determine whether CCN1 was O-fucosylated or not, we puri-
fied recombinant CCN1 protein from the CM of HT1080-CCN1-MH
cells (Fig. 2A). The cells were cultured in serum-free medium with
heparin sepharose beads, and the proteins bound to heparin were
eluted with NaCl, followed by affinity purification using Ni–NTA
agarose (Fig. 2A). Purified CCN1 protein was digested with trypsin,and the resulting peptides were analyzed by MALDI-TOF MS
(Fig. 2B). The observed masses (m/z 2706.4 and 2868.5) corre-
sponded well to the expected masses of the trypsin-digested pep-
tide 229CIVQTTSWSQCSKTCGTGISTR250, which contains a putative
O-fucosylation site (Thr242) modified by fucose (dHex) and
fucose-glucose disaccharide (dHex-Hex); the dHex:dHex-Hex ratio
is approximately 1:2 (Fig. 2B). Non-fucosylated peptide was not
observed at the expected mass (m/z 2560.4) of the trypsin-
digested peptide 229CIVQTTSWSQCSKTCGTGISTR250 (Fig. 2B), indi-
cating that all secreted CCN1 was O-fucosylated. To confirm the
sequence of the peptides and O-fucosylation site, MS/MS analysis
was performed (Fig. 2C). Addition of 146 Da (fucose, upper) and
308 Da (fucose-glucose, lower), resulting from O-fucosylation,
was observed in the y9–y12 and y16 ions but not in the y5–y8 ions,
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Fig. 4. Knockdown of Pofut2 decreases CCN1 secretion. (A) Knockdown of Pofut2 using siRNAs. HT1080-CCN1-MH cells were treated with the indicated siRNAs for 72 h. Total
RNAs were isolated from each cell line, and semi-quantitative RT-PCR was performed to confirm the knockdown efficiency of each gene. (B) Effect of knockdown of Pofut2 on
CCN1 secretion. Each cell was cultured with 50 lg/mL soluble heparin. After 24 h, each cell lysate and CM were collected, and the samples were electrophoresed and
immunoblotted with anti-c-myc antibody. The membrane after immunoblotting was visualized with CBB.
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residue (Fig. 2C).
3.2. O-fucosylation of CCN1 regulates its secretion
Secretion is an initial step for CCN1 to function as a ligand. To
clarify the role of O-fucosylation in CCN1 secretion, we established
an O-fucosylation-defective mutant CCN1-overexpressing HT1080
cell line, HT1080-CCN1/T242A-MH cells. An equal amount of
exogenous CCN1 in the stable cell lines was confirmed by western
blot and semi-quantitative RT-PCR (Fig. 3A and B). Since CCN1 has
high affinity for cell surface HSPGs [11] and is predicted to localize
at the cell surface, along with HSPGs, we examined whether
O-fucosylation affects cell surface localization of CCN1. To observe
cell surface localization, we stained for CCN1 protein without
permeabilization. Wild-type CCN1 was stained high levels at the
cellular membrane; however, compared with wild-type CCN1,
the O-fucosylation-defective T242A mutant CCN1 was stained at
low levels (Fig. 3C), although equal amounts of wild-type and
T242A mutant CCN1 were expressed at the protein level
(Fig. 3A). Furthermore, treatment with heparin in these cells abol-
ished cell surface expression of CCN1 (Fig. 3C), suggesting that
extracellular CCN1 was associated with HSPGs and existed at the
cell surface. These results suggested that O-fucosylation of CCN1
regulates its trafficking to extracellular spaces.
From the data of the immunofluorescence analyses, it is sug-
gested that O-fucosylation of CCN1 regulates its secretion. To con-
firm this hypothesis, we analyzed the effect of O-fucosylation on its
secretion by immunoblotting. Although O-fucosylated wild-type
CCN1 was secreted into CM, the O-fucosylation-defective T242A
mutant CCN1 significantly inhibited the secretion (Fig. 3D). These
results demonstrated that O-fucosylation of CCN1 was required
for its secretion.
3.3. Knockdown of Pofut2 decreases CCN1 secretion
It was reported that O-fucosylation of TSR1 was catalyzed by
Pofut2 [25,26]. To exclude the possibility that the decrement of
CCN1 secretion was due to the mutation of Thr242 to Ala, we
performed RNAi experiments using two siRNAs targeting
Pofut2. Knockdown efficiency of each siRNA was confirmed by
semi-quantitative RT-PCR (Fig. 4A), and knockdown of Pofut2
decreased secretion of CCN1 (Fig. 4B). These results suggested thatPofut2-mediated O-fucosylation of CCN1 at the Thr242 residue in
TSR1 regulates its secretion.
4. Discussion
In this report, we demonstrated the first evidence that human
CCN1 is O-fucosylated at the Thr242 residue in TSR1 using
MALDI-TOF MS and MS/MS analyses (Fig. 2B and C), and Pofut2-
mediated O-fucosylation of CCN1 regulates its secretion
(Figs. 3D and 4B). In humans, CCN family proteins include 6 mem-
bers, CCN1–6, and all CCN family proteins have conserved O-
fucosylation consensus sequence, C-X2–3-(S/T)-C-X2-G, of Pofut2
in TSR1 (Fig. 1B); however, no CCN family protein has been
reported to be O-fucosylated at the conserved Ser/Thr residue.
We are the first to report that human CCN1 is O-fucosylated at
Thr242. We would like to investigate O-fucosylation of other CCN
family proteins and analyze the effect of O-fucosylation on their
functions in the future.
In the manuscript, we purified recombinant CCN1 from CM of
HT1080-CCN1-MH cells, and the proteins were analyzed by
MALDI-TOF MS (Fig. 2). From the data of the MS analysis, secreted
CCN1 did not contain non-O-fucosylated CCN1 (Fig. 2B). These
results suggested that O-fucosylation of CCN1 is essential for its
proper secretion. Actually, we also demonstrated that the secretion
level of the O-fucosylation-defective T242A mutant CCN1 was
lower than wild-type CCN1 (Fig. 3D), and knockdown of Pofut2
decreased the secreted level of CCN1 (Fig. 4B); however, intracellu-
lar localization of the T242A mutant CCN1 at the ER and the Golgi
apparatus was similar to wild-type CCN1 (data not shown). Fur-
thermore, cell surface localization of the T242A mutant CCN1
was lower than that of wild-type (Fig. 3C), and the affinity for hep-
arin beads was not altered between wild-type and the T242A
mutant CCN1 (data not shown). These results suggested that O-
fucosylation of CCN1 might regulate the trafficking from the Golgi
apparatus to the extracellular region. In general, protein glycosyla-
tion is important for proper folding. O-fucosylation of CCN1 is
probably important for its folding, and as a result, non-O-
fucosylated CCN1 might not be transported properly. Further anal-
ysis is required to clear the recognition step of O-fucosylation to
transport properly.
In conclusion, human CCN1 is O-fucosylated at the Thr242
residue by Pofut2, and the secretion of CCN1 is regulated by
O-fucosylation. Our results may be contributory to extending the
Y. Niwa et al. / FEBS Letters 589 (2015) 3287–3293 3293knowledge about Pofut2-mediated O-fucosylation. Furthermore, it
was reported that aberrant expression of CCN1 induces tumorige-
nesis and tumor progression [15–20]. Since the secretion of CCN1
is an initial step for its biological functions, O-fucosylation of
CCN1 might be a novel diagnostic marker or a molecular target
for cancer therapeutics.
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